Advanced search

Vol 82, No 4 (2024)
Review paper
Published online: 2024-03-18

open access

View PDF Download PDF file
Page views 146
Article views/downloads 168
Get Citation

Connect on Social Media

Connect on Social Media

Acute coronary syndromes in patients with cancer: Recent advances

Gemina Doolub12, Aditya S Bharadwaj3, Mamas Mamas1
DOI: 10.33963/v.phj.99845
Pubmed: 38506569
Pol Heart J 2024;82(4):375-381.

Abstract

Coronary artery disease is presently one of the leading causes of death among cancer survivors. Due to the number of cancer survivors projected to reach 26 million by 2040 managing coronary disease in this population presents a unique challenge. Cancer patients face an elevated risk of atherosclerotic disease due to shared cardiovascular risk factors and the cardiotoxic effects of cancer therapies, predisposing them to acute coronary syndromes. Challenges in treating cancer patients presenting with acute coronary syndromes include atypical presentations, obscured symptoms, and the impact of cancer-related processes on traditional biomarkers. This review explores the complexities of acute coronary syndrome management in cancer patients, addressing challenges involved, recent advances in percutaneous strategies, pharmacology, and considerations for these high-risk individuals. This review discusses a balance between invasive vs. medical strategy, technical advances in multimodal imaging, intravascular physiology, intracoronary imaging, and evolving stent options, highlighting the need for tailored approaches in this complex patient population.

Keywords: acute coronary syndromecancercardiovascular disease

Article available in PDF format

View PDF Download PDF file

References

  1. Mamas MA, Brown SA, Sun LY. Coronary artery disease in patients with cancer: It's always the small pieces that make the bigger picture. Mayo Clin Proc. 2020; 95(9): 1819–1821.
    CrossRefPubMed
  2. Wang Z, Fan Z, Yang L, et al. Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors. Front Cardiovasc Med. 2023; 10: 1014400.
    CrossRefPubMed
  3. Cancer society. Cancer Treatment & Survivorship Facts & Figures 2019-2021 2019.
  4. Statistics and graphs. Office of Cancer survivorship. National Cancer institute: Division of cancer control & population sciences. Nov 2022. https://cancercontrol.cancer.gov/ocs/statistics#stats (accessed: January 11, 2024).
  5. Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016; 133(11): 1104–1114.
    CrossRefPubMed
  6. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010; 15(6): 556–565.
    CrossRefPubMed
  7. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33(7): 1674–1685.
    CrossRefPubMed
  8. Costa IB, Andrade FT, Carter D, et al. Challenges and management of acute coronary syndrome in cancer patients. Front Cardiovasc Med. 2021; 8: 590016.
    CrossRefPubMed
  9. Grossman E, Messerli FH, Boyko V, et al. Is there an association between hypertension and cancer mortality? Am J Med. 2002; 112(6): 479–486.
    CrossRefPubMed
  10. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020; 22(11): 1945–1960.
    CrossRefPubMed
  11. Caine GJ, Stonelake PS, Lip GYH, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002; 4(6): 465–473.
    CrossRefPubMed
  12. Potts JE, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J. 2019; 40(22): 1790–1800.
    CrossRefPubMed
  13. Doolub G, Mamas MA. Percutaneous coronary angioplasty in patients with cancer: Clinical challenges and management strategies. J Pers Med. 2022; 12(9): 1372.
    CrossRefPubMed
  14. Yadav M, Généreux P, Giustino G, et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016; 32(2): 226–233.
    CrossRefPubMed
  15. Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: A review. Ann Palliat Med. 2018; 7(2): 265–273.
    CrossRefPubMed
  16. Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019; 40(31): 2632–2653.
    CrossRefPubMed
  17. Raposeiras-Roubín S, Abu-Assi E, Muñoz-Pousa I, et al. Usefulness of bleeding after acute coronary syndromes for unmasking silent cancer. Am J Cardiol. 2020; 125(12): 1801–1808.
    CrossRefPubMed
  18. Kirresh A, White L, Mitchell A, et al. Radiation-induced coronary artery disease: a difficult clinical conundrum. Clin Med (Lond). 2022; 22(3): 251–256.
    CrossRefPubMed
  19. Borges N, Kapadia S. Radiation-induced CAD: incidence, diagnosis, and management outcomes. American College of Cardiology. 2018. https://www.acc.org/Latest-in-Cardiology/Articles/2018/05/24/01/44/Radiation-Induced-CAD (accessed: January 11, 2024).
  20. Cuomo JR, Javaheri SP, Sharma GK, et al. How to prevent and manage radiation-induced coronary artery disease. Heart. 2018; 104(20): 1647–1653.
    CrossRefPubMed
  21. Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013; 127(14): 1476–1485.
    CrossRefPubMed
  22. Reed GW, Rossi JE, Masri A, et al. Long-Term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv. 2016; 9(6): e003483.
    CrossRefPubMed
  23. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
    CrossRefPubMed
  24. Mohamed MO, Van Spall HGC, Kontopantelis E, et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care. 2021; 10(8): 829–839.
    CrossRefPubMed
  25. Balanescu DV, Donisan T, Deswal A, et al. Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. Int J Cardiol. 2020; 313: 1–8.
    CrossRefPubMed
  26. Bharadwaj A, Potts J, Mohamed MO, et al. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J. 2020; 41(23): 2183–2193.
    CrossRefPubMed
  27. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol. 2016; 142(2): 471–479.
    CrossRefPubMed
  28. Beltrame JF. Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA). J Intern Med. 2013; 273(2): 182–185.
    CrossRefPubMed
  29. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017; 38(3): 143–153.
    CrossRefPubMed
  30. Stepien K, Nowak K, Szlosarczyk B, et al. Clinical characteristics and long-term outcomes of MINOCA accompanied by active cancer: A retrospective insight into a Cardio-Oncology Center Registry. Front Cardiovasc Med. 2022; 9: 785246.
    CrossRefPubMed
  31. Zaghlol R, Dey A, Barac A. Takotsubo and cancer: Takotsubo cardiomyopathy in the era of emerging cancer therapies. Eur Heart J. 2020; 41(48): 4547–4549.
    CrossRef
  32. Sattler K, El-Battrawy I, Gietzen T, et al. Prevalence of cancer in Takotsubo cardiomyopathy: Short and long-term outcome. Int J Cardiol. 2017; 238(7): 159–165.
    CrossRefPubMed
  33. Zaghlol R, Kashyap K, Al-Shbool G, et al. Usefulness of malignancy as a predictor of worsein-hospital outcomes in patients with takotsubo cardiomyopathy. Am J Cardiol. 2019; 123(6): 995–1001.
    CrossRefPubMed
  34. El-Battrawy I, Santoro F, Stiermaier T, et al. Prevalence and long-term prognostic impact of malignancy in patients with Takotsubo syndrome. Eur J Heart Fail. 2018; 20(4): 816–818.
    CrossRefPubMed
  35. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017; 38(3): 143–153.
    CrossRefPubMed
  36. Dastidar AG, Baritussio A, De Garate E, et al. Prognostic role of CMR and conventional risk factors in myocardial infarction with nonobstructed coronary arteries. JACC Cardiovasc Imaging. 2019; 12(10): 1973–1982.
    CrossRefPubMed
  37. Ferrante G, Rao SV, Jüni P, et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials. JACC Cardiovasc Interv. 2016; 9(14): 1419–1434.
    CrossRefPubMed
  38. Gargiulo G, Giacoppo D, Jolly SS, et al. Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: meta-analysis of individual patient data from 7 multicenter randomized clinical trials. Circulation. 2022; 146(18): 1329–1343.
    CrossRefPubMed
  39. Valgimigli M, Saia F, Guastaroba P, et al. Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. JACC Cardiovasc Interv. 2012; 5(1): 23–35.
    CrossRefPubMed
  40. Seto AH, Roberts JS, Abu-Fadel MS, et al. Real-time ultrasound guidance facilitates transradial access: RAUST (Radial Artery access with Ultrasound Trial). JACC Cardiovasc Interv. 2015; 8(2): 283–291.
    CrossRefPubMed
  41. Munoz-Gonzalez, E. et al. PCI in patients with cancer. Cardiac Interventions Today. https://citoday.com/articles/2019-jan-feb/pci-in-patients-with-cancer (accessed: February 25, 2024).
  42. Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019; 381(15): 1411–1421.
    CrossRefPubMed
  43. Kim JW, Dayah TJ, Javaid A, et al. Reclassification of treatment strategy with fractional flow reserve in cancer patients with coronary artery disease. Medicina (Kaunas). 2022; 58(7): 884.
    CrossRefPubMed
  44. Donisan T, Dayah T, Balanescu D, et al. Clinical outcomes after fractional flow reserve-guided treatment of oncology patients. J Clin Oncol. 2018; 36(Suppl 15): e22106.
    CrossRef
  45. Madder RD, Seth M, Sukul D, et al. Rates of intracoronary imaging optimization in contemporary percutaneous coronary intervention: a report from the BMC2 registry. Circ Cardiovasc Interv. 2022; 15(10): e012182.
    CrossRefPubMed
  46. Munoz-Gonzalez E, Poulin MF, Goel M, et al. PCI in patients with cancer: Approaches for successfully treating this challenging patient population when invasive coronary procedures are needed. Cardiac Interventions Today. 2019.
  47. de la Torre Hernandez JM, Hernandez FH, Alfonso F, et al. Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions. J Am Coll Cardiol. 2011; 58(4): 351–358.
    CrossRefPubMed
  48. Richards G, Johnson T. A vision of percutaneous coronary revascularisation in 2021: How to take advantage of intra-coronary imaging to perform more effective PCI. JRSM Cardiovasc Dis. 2021; 10: 20480040211049978.
    CrossRefPubMed
  49. Räber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018; 39(35): 3281–3300.
    CrossRefPubMed
  50. Johnson TW, Räber L, Di Mario C, et al. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2019; 40(31): 2566–2584.
    CrossRefPubMed
  51. Lotfi A, Jeremias A, Fearon WF, et al. Expert consensus statement on the use of fractional flow reserve, intravascular ultrasound, and optical coherence tomography: a consensus statement of the Society of Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2014; 83(4): 509–518.
    CrossRefPubMed
  52. Iliescu CA, Cilingiroglu M, Giza DE, et al. "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017; 194: 83–91.
    CrossRefPubMed
  53. Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015; 65(8): 805–815.
    CrossRef
  54. Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv. 2016; 9(5): 426–436.
    CrossRefPubMed
  55. Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015; 373(21): 2038–2047.
    CrossRefPubMed
  56. Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020; 382(13): 1208–1218.
    CrossRefPubMed
  57. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019; 381(21): 2032–2042.
    CrossRefPubMed
  58. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: Third report of the international DBC consensus group. JACC Cardiovasc Interv. 2020; 13(12): 1391–1402.
    CrossRefPubMed
  59. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol. 2012; 60(24): 2473–2480.
    CrossRefPubMed
  60. Mathey DG, Wendig I, Boxberger M, et al. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention. 2011; 7 Suppl K: K61–K65.
    CrossRefPubMed
  61. Scheller B, Ohlow MA, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. 2020; 15(17): 1527–1533.
    CrossRefPubMed
  62. Valgimigli M, Smits PC, Frigoli E, et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J. 2022; 43(33): 3100–3114.
    CrossRefPubMed
  63. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019; 321(24): 2414–2427.
    CrossRefPubMed
  64. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44(38): 3720–3826.
    CrossRefPubMed
  65. Leszek P, Klotzka A, Bartuś S, et al. A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts - cardiologists and oncologists. Kardiol Pol. 2023; 81(10): 1047–1063.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Polish Heart Journal (Kardiologia Polska)

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice